Related references
Note: Only part of the references are listed.Exploring the NK cell platform for cancer immunotherapy
Jacob A. Myers et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer
May Daher et al.
CANCER DISCOVERY (2021)
Engineering the next generation of CAR-NK immunotherapies
Alexander Biederstaedt et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)
An engineered IL-2 partial agonist promotes CD8+ T cell stemness
Fei Mo et al.
NATURE (2021)
PRDM1 decreases sensitivity of human NK cells to IL2-induced cell expansion by directly repressing CD25 (IL2RA)
Burcu Akman et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2021)
NK cells for cancer immunotherapy
Noriko Shimasaki et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts
Yu Yang Ng et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Transcriptional Regulation of Natural Killer Cell Development and Functions
Dandan Wang et al.
CANCERS (2020)
An Improved Protocol for the Production of Lentiviral Vectors
Logan Y. Brown et al.
STAR PROTOCOLS (2020)
The role of cytokines in the regulation of NK cells in the tumor environment
Gordana M. Konjevic et al.
CYTOKINE (2019)
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control
Zhichen Sun et al.
NATURE COMMUNICATIONS (2019)
JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation
Dagmar Gotthardt et al.
FRONTIERS IN IMMUNOLOGY (2019)
An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression
Rika Fujii et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
NKG2D and Its Ligands: One for All, All for One
Alessandra Zingoni et al.
FRONTIERS IN IMMUNOLOGY (2018)
A homing system targets therapeutic T cells to brain cancer (Publication with Expression of Concern. See vol. 567, pg. 132, 2019)
Heba Samaha et al.
NATURE (2018)
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Alex M. Abel et al.
FRONTIERS IN IMMUNOLOGY (2018)
Biology and regulation of IL-2: from molecular mechanisms to human therapy
Rosanne Spolski et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells
Youssef Jounaidi et al.
CANCER RESEARCH (2017)
CIS is a potent checkpoint in NK cell-mediated tumor immunity
Rebecca B. Delconte et al.
NATURE IMMUNOLOGY (2016)
IL-15 Superagonist Expands mCD8+T, NK and NKT Cells after Burn Injury but Fails to Improve Outcome during Burn Wound Infection
Naeem K. Patil et al.
PLOS ONE (2016)
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
Rizwan Romee et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
The head and neck cancer immune landscape and its immunotherapeutic implications
Rajarsi Mandal et al.
JCI INSIGHT (2016)
In-vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15
Ana M. Vuletic et al.
MELANOMA RESEARCH (2015)
Activated regulatory T cells suppress effector NK cell responses by an IL-2-mediated mechanism during an acute retroviral infection
Elisabeth Littwitz-Salomon et al.
RETROVIROLOGY (2015)
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy
Denise Skrombolas et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Fusion protein linkers: Property, design and functionality
Xiaoying Chen et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
Wei Liao et al.
IMMUNITY (2013)
Natural killer cell deficiency
Jordan S. Orange
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells
Georg Gasteiger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Occurrence of Nodular Lymphocyte-Predominant Hodgkin Lymphoma in Hermansky-Pudlak Type 2 Syndrome Is Associated to Natural Killer and Natural Killer T Cell Defects
Luisa Lorenzi et al.
PLOS ONE (2013)
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi et al.
JOURNAL OF IMMUNOLOGY (2011)
Pharmacologic Administration of Interleukin-2 Inducing a Systemic Autophagic Syndrome?
Antonio Romo de Vivar Chavez et al.
CYTOKINE THERAPIES: NOVEL APPROACHES FOR CLINICAL INDICATIONS (2009)
Structural Biology of Shared Cytokine Receptors
Xinquan Wang et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Hiroyuki Fujisaki et al.
CANCER RESEARCH (2009)
Expansion and Activation of Natural Killer Cells for Cancer Immunotherapy
Duck Cho et al.
KOREAN JOURNAL OF LABORATORY MEDICINE (2009)
Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses
William H. D. Hallett et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
CD4+-CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer
MJ Smyth et al.
JOURNAL OF IMMUNOLOGY (2006)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells
KV Konstantinidis et al.
EXPERIMENTAL HEMATOLOGY (2005)
Negative regulation of cytokine signaling and immune responses by SOCS proteins
A Yoshimura et al.
ARTHRITIS RESEARCH & THERAPY (2005)
NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity
PA Albertsson et al.
TRENDS IN IMMUNOLOGY (2003)
Share Paper
